Chlamydia trachomatis and Neisseria gonorrhoeae by Transcription-Mediated Amplification (TMA), SurePath
2001551
Ordering Recommendation
Can be used to detect Chlamydia trachomatis and Neisseria gonorrhoeae in SurePath specimens.
Mnemonic
CTNG SP
Methodology
Transcription-Mediated Amplification
Performed
Sun-Sat
Reported
1-3 days  
New York DOH Approval Status
This test is New York DOH approved.
Submit With Order
Specimen Required
Patient Preparation
  
Collect
Cervical brush in SurePath liquid-based Pap test Media. Refer to "Sample Collection for the Diagnosis of STD" under Specimen Handling at www.aruplab.com for specific specimen collection and transport instructions.  
Specimen Preparation
Vortex SurePath media and transfer a 1 mL aliquot to APTIMA Combo 2 transport media (ARUP supply #42711) within 24 hours of collection. Available online through eSupply using ARUP Connect™ or contact ARUP Client Services at (800) 522-2787. To reduce the potential for contamination SurePath specimens should be poured off, using sterile technique, into the APTIMA Specimen Transfer Tube prior to Cytology Testing.  
Storage/Transport Temperature
Refrigerated.  
Unacceptable Conditions
Specimens in any transport media other than indicated above. Specimens from patients that are less than 16 years of age.  
Remarks
Specimen source is required.  
Stability
SurePath Media: Ambient: 24 hours; Refrigerated: 48 hours; Frozen: 1 week
APTIMA
 Media: Ambient: 2 weeks; Refrigerated: 1 month; Frozen: 1 month  
Reference Interval
Negative  
Interpretive Data
Use of transport media other than the manufacturer's collection kit (eg, SurePath) may result in reduced sensitivity. Specimens should be collected and transported following the instructions in "Sample Collection for the Diagnosis of STD Using Nucleic Acid Amplification Tests" under Specimen Handling at www.aruplab.com.

Positive results are confirmed using an alternative nucleic acid target in accordance with the CDC guidelines. See: Screening Tests To Detect Chlamydia trachomatis and Neisseria gonorrhoeae Infections-2002. (http://www.cdc.gov/std/LabGuidelines/rr5115.pdf)

This test is intended for medical purposes only and is not valid for the evaluation of suspected sexual abuse or for other forensic purposes.
In certain contexts, culture may be required to meet applicable laws and regulations for diagnosis of C. trachomatis and N. gonorrhoeae infections.

See Compliance Statement B: www.aruplab.com/CS
Statement B: This test was developed and its performance characteristics determined by ARUP Laboratories. The U.S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.
 
Note
The performance of this test has not been evaluated in adolescents less than 16 years of age.
CPT Code(s)
87491;87591
Components
Component Test Code*Component Chart Name
2001552C. trachomatis by TMA, SurePath
2001553N. gonorrhoeae by TMA, SurePath
2005507Specimen Source
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
Aliases
  • Chlamydia and GC TMA panel
  • CT/GC TMA SurePath
  • Gonorrhea SurePath
  • Nucleic Acid Amplification Test (NAAT)